A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study in Healthy Volunteers and a Double-blind, Placebo-controlled, Multiple-ascending-dose Study in Patients With Parkinson's Disease to Evaluate the Safety, Tolerability, and PK/PD of LY3962681

JRCT ID: jRCT2031240316

Registered date:03/09/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Parkinson's Disease
• Date of first enrollment: 17/09/2024
• Target sample size: 108
• Countries of recruitment: United States,Japan
• Study type: Interventional

Intervention(s)

Drug: LY3962681
IT injection
Placebo
IT injection

Drug: LY3962681
IT injection
Placebo
IT injection

[Study Arms]
Experimental: LY3962681 (SAD)
Single ascending dose of LY3962681 or placebo administered intrathecally (IT) to healthy volunteers.

Experimental: LY3962681 (MAD)
Multiple ascending doses of LY3962681 or placebo administered IT to participants with Parkinson's disease.

Outcome(s)

Primary Outcome

1. Incidence of Serious Adverse Events (SAEs)
[Time Frame: Up to 76 weeks]
2. Incidence of Treatment Emergent Adverse Events (TEAEs)
[Time Frame: Up to 76 weeks]
3. Number of discontinuations due to Adverse Events (AEs)
[Time Frame: Up to 76 weeks]

Key inclusion & exclusion criteria

• Age minimum: >= 30age old
• Age maximum: <= 80age old
• Gender: Both

Include criteria

- Participant is overtly healthy as determined by medical evaluation. Rescreening is allowed in this study.
- A Montreal Cognitive Assessment score greater than 26.
- Stable use of background medications at least 8 weeks prior to IP administration, including but not limited to those used for treatment of Parkinson's disease (including deep brain stimulation), and the investigator must expect that participant can tolerate a minimum of 6 months without dose adjustment.

MAD study only
- Participant has a diagnosis of Parkinson's disease per UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.
- Hoehn and Yahr Stage 1 to 2 in the practically defined OFF state.
- A positive result on CSF alpha-synuclein Seed Amplification Assay. (A prior positive result [within 1 year of screening] accepted with sponsor approval if patient did not participate in another Parkinson's disease clinical trial during this period.) (US and Japan only)
- UPSIT score of 10 percentile or less, corrected for age and sex (EU and UK only).
- An abnormal DaT-SPECT consistent with parkinsonism. (History of an abnormal DaTSPECT with the report confirmed by study investigator will be accepted.)
- For participants not taking Parkinson's disease medications, not expected to initiate treatment within 6 months.
- Have a body weight within 40 kg (88 pounds) to 110 kg (242 pounds), inclusive, and body mass index within the range of 17 to 34 kg/m2, inclusive.

Exclude criteria

- MAD study only: Significant neurological disease affecting the central nervous system other than Parkinson's disease that may be a cause for the participant's clinical symptoms or may confound study objectives.
- Current concomitant disease or serious or unstable illnesses, including central nervous system (SAD study only), cardiovascular, hepatic, renal, gastroenterology, respiratory, endocrinologic, neurologic (MAD study only: other than Parkinson's disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the conduct of the study or that would, in the opinion of the investigator, pose an unacceptable safety risk to the participant.
- Participant is generally frail or has any medical disorders that, in the opinion of the investigator, could interfere with study-related procedures (including safe performance of IT injection or LP), such as prohibitive spinal diseases, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, or increased intracranial pressure.
- Have a 12-lead ECG abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.
- MAD study only: Treatment with continuous intestinal delivery Parkinson's disease medication (for example, Duodopa).

Other protocol-defined inclusion/exclusion criteria may apply.

Related Information

• Primary Sponsor: Wakayama Naohiko
• Secondary ID(s): NCT06565195